The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PSTV | -59.4% | -98.51% | -56.85% | -100% |
| S&P | +13.19% | +87.83% | +13.42% | +586% |
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.40M | -4.1% |
| Gross Profit | $1.31M | 7.1% |
| Gross Margin | 93.84% | 9.8% |
| Market Cap | $67.87M | 688.4% |
| Market Cap / Employee | $3.23M | 0.0% |
| Employees | 21 | 5.0% |
| Net Income | -$4.42M | -53.9% |
| EBITDA | -$4.40M | -23.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $13.29M | 986.6% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.02M | -99.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -191.33% | -64.1% |
| Return On Invested Capital | 137.93% | 65.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.58M | 30.3% |
| Operating Free Cash Flow | -$2.55M | 30.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -1.31 | -0.63 | -0.25 | 20.77 | -2002.11% |
| Price to Sales | 1.16 | 2.66 | 13.68 | 13.97 | 597.27% |
| Price to Tangible Book Value | -1.12 | -0.57 | -0.24 | 27.87 | -2963.00% |
| Enterprise Value to EBITDA | -1.78 | -1.20 | -45.38 | -12.94 | 357.72% |
| Return on Equity | -522.5% | - | |||
| Total Debt | $3.37M | $0.04M | $0.03M | $0.02M | -99.38% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
